Advertisement

Pfizer's 2Q profit sinks 79% but tops forecasts

By Associated Press  |  July 29, 2014

Pfizer's second-quarter earnings plunged 79% from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.

Tax reform fears driving Big Pharma mergers

Tax reform fears driving Big Pharma mergers

By Beth Kutscher  |  July 19, 2014

The rumblings that corporate tax reform will close favorable loopholes for pharmaceutical and biotechnology companies are getting louder, fueling a rush of high-dollar cross-border deals.

Pfizer withdraws spurned offer for AstraZeneca

Pfizer withdraws spurned offer for AstraZeneca

By Associated Press  |  May 26, 2014

Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.

Drug prices spotlighted in AstraZeneca deal

By Beth Kutscher  |  May 24, 2014

With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from Pfizer to create the world's largest pharmaceutical company.

AstraZeneca holding firm against Pfizer's advances

AstraZeneca holding firm against Pfizer's advances

By Beth Kutscher  |  May 23, 2014

With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from rival Pfizer to create the world's largest pharmaceutical company. The record-setting offer is just one of a slew of mega-deals this year in the pharmaceutical and...

Pfizer faces lawsuits that claim Lipitor caused diabetes

Pfizer faces lawsuits that claim Lipitor caused diabetes

By Joe Carlson  |  May 17, 2014

Several hundred women are suing Pfizer in federal court, alleging the company knew that women taking Lipitor faced an increased risk of developing Type 2 diabetes and that Pfizer's warning label did not clearly describe that risk.

AstraZeneca rejects sweetened Pfizer takeover bid

AstraZeneca rejects sweetened Pfizer takeover bid

By Associated Press  |  May 02, 2014

Pharmaceutical company AstraZeneca on Friday flatly rejected drug maker Pfizer's sweetened takeover bid — worth $106 billion — just hours after it was levelled, describing it as inadequate.

AstraZeneca shares soar on Pfizer interest

AstraZeneca shares soar on Pfizer interest

By Associated Press  |  April 28, 2014

Shares in Anglo-Swedish drugmaker AstraZeneca jumped 15% on Monday after U.S. pharmaceutical company Pfizer said it offered to buy the company for around $100 billion.

Novartis overtakes Pfizer as top drug company

Novartis overtakes Pfizer as top drug company

By Michael Sandler  |  April 13, 2014

A robust sales year for three of Novartis' medications allowed the firm to pass reeling Pfizer for the top spot on Modern Healthcare's annual list of largest publicly traded pharmaceutical companies.

Two drugs show promise in slowing breast cancer

By Wall Street Journal  |  April 07, 2014

Two drugs from Pfizer and Eli Lilly & Co. that employ a new therapeutic approach showed promise in slowing the course of breast cancer, according to early-stage research released on Sunday.

Advertisement
Modern Healthcare Daily

The top stories in healthcare business every day

The Modern Healthcare Daily News App provides you with registration-free access to the top trending healthcare business news. It's the only news you need each day.

Sponsored by